Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This malignancy was most consistent with SMARCB1-deficient epithelioid malignant peripheral nerve sheath tumour, although a significant differential was proximal-type epithelial sarcoma.
|
29761250 |
2019 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The oncomiR role of miR-206 is crucial but not exclusive in SMARCB1 negative soft tissue sarcomas and miR-206 has an antiproliferative effect on a normal human fibroblast cell line.
|
30111166 |
2018 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas.
|
27223121 |
2016 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We evaluated BRG1 and INI1 expression in 12 SCCOHTs and in a series of 122 tumors that could mimic SCCOHT morphologically: 9 juvenile granulosa cell tumors, 47 adult granulosa cell tumors, 33 high-grade ovarian serous carcinomas, 9 desmoplastic round cell tumors, 13 Ewing sarcomas (5 from the pelvis and 8 from soft tissues), 1 round cell sarcoma associated with CIC-DUX4 translocation from soft tissue (thigh), 1 case of high-grade endometrial stromal sarcoma of the ovary, and 9 melanomas.
|
26135561 |
2015 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Among controls, only the SMARCB1-immunonegative myoepithelial carcinomas displayed SMARCB1 homozygous deletions in 3/5 cases, while no gene specific abnormalities were seen among all other histologic subtypes of sarcomas tested regardless of the SMARCB1 protein status.
|
24585572 |
2014 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed the frequency of GPC3 protein expression, GPC3 mRNA, and serum-soluble GPC3 levels in 71 cases of tumors with loss of SMARCB1/INI1 protein expression, including 14 MRTs, 48 epithelioid sarcomas (ES) (proximal-type, 21; distal-type, 27), 4 extraskeletal myxoid chondrosarcomas, and 5 pediatric undifferentiated soft-tissue sarcomas.
|
23084579 |
2013 |
Sarcoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
|
18973917 |
2009 |
Sarcoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thus, alterations of the INI1 gene with consequent loss of expression identified a population of undifferentiated sarcomas lacking classic rhabdoid morphology in young patients, with evidence of favorable survival.
|
18997735 |
2009 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group.
|
19141382 |
2009 |
Sarcoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Thus, alterations of the INI1 gene with consequent loss of expression identified a population of undifferentiated sarcomas lacking classic rhabdoid morphology in young patients, with evidence of favorable survival.
|
18997735 |
2009 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed the status of SMARCB1/INI1 protein expression in 93 cases of sarcomas associated with chromosomal translocation involving EWS, comprising 52 Ewing's sarcoma/primitive neuroectodermal tumors, 24 extraskeletal myxoid chondrosarcomas (EMCS), 14 clear cell sarcomas of soft tissue, 2 desmoplastic small round cell tumors, and 1 myxoid/round cell liposarcoma.
|
18580682 |
2008 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
|
15899790 |
2005 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, we utilized immunohistochemistry and FISH to study INI1 expression and 22q dosages, respectively, in 40 composite rhabdoid tumors, including 16 meningiomas, 15 carcinomas, three melanomas, two sarcomas, two glioblastomas, and 1 neuroblastoma.
|
15761491 |
2005 |